IOWA | Health and Human Services

Iowa Medicaid Drug Utilization Review (DUR) Commission

May 7, 2025

Time: 9:30 a.m. – 1:30 p.m. CT
Location: Virtual
Teams Meeting: https://teams.microsoft.com/l/meetup-join/19%3ameeting_MmM0NWFjNjQtMWY0NS00Y2JkLWE0MjYtYmU1MGMyNzA4NWYw%40thread.v2/0?context=%7b%22Tid%22%3a%228d2c7b4d-085a-4617-8536-38a76d19b0da%22%2c%22Oid%22%3a%22982a0572-2333-4ea7-b2e0-b02af2367c61%22%7d

Meeting ID: 238 580 134 905
Passcode: 7zL7CK3a

Final Agenda

1. Welcome & Introductions
    a) Commission Members and Staff
2. Commission Business
    a) Approval of the February 5, 2025 Meeting Minutes
    b) February 2025 DUR Recommendation Letter to DHHS
    c) Follow-Up from Previous Meeting(s)
    d) DUR Recommendation Process
3. Iowa Medicaid Pharmacy Update
4. Prevalence Report Summaries
    a) Wellpoint Iowa
    b) Fee-for-Service
    c) Iowa Total Care
    d) Molina Healthcare of Iowa
    e) Comparative Summary
5. Public Comment* (Complete Speaker Conflict of Interest Disclosure Form)
    - Verbal - Must **pre-register** to provide verbal public comment and submit a completed conflict of interest disclosure. Five (5) minute maximum limit. For hybrid meetings, verbal public comment will be allowed in person and virtually.
    - Written – Must submit written comments and a completed conflict of interest disclosure.
    - **All submissions must be received no later than 4:30 p.m. CST April 29, 2025.**
    - **Email to pba_iadur@optum.com.**
6. Retrospective DUR
    a) Data Presentation(s)
        i. Stimulant Medication Utilization without Supporting Diagnosis – Update
        ii. Evaluation of Dornase Alpha in Cystic Fibrosis Patients on Modulator Therapy
        iii. LABA + ICS in COPD
    b) Proposal(s)
        i. Drug-Drug Interaction: Amlodipine with Simvastatin or Lovastatin
        ii. Opioid Reversal Agent Frequency in Members with MME ≥90
    c) Commission Recommendations for Retrospective DUR Agenda Topics

7. Prospective DUR
    a) Concurrent Use of GLP-1 RA and DPP-1 Inhibitor – Initial Review
    b) 90-Day Supply Allowance Prescription List - Update
8. Break (10 minutes)
9. Prior Authorization
    a) Adenosine Triphosphate-Citrate Lyase (ACL) Inhibitors – Initial Review
    b) Givinostat (Duvyzat) – Initial Review
    c) Lebrikizumab-lbkz (Ebglyss) - Initial Review
    d) Nemolizumab-ilto (Nemluvio) – Initial Review
    e) Aprocitentan (Tryvio) – Second Review
    f) CNS Stimulants and Atomoxetine – Second Review
    g) Direct Oral Anticoagulants – Second Review
    h) Letermovir (Prevymis) – Second Review
    i) Peanut (*Arachis hypogaea*) Allergen Powder-DNFP (Palforzia) – Second Review
    j) Oxybate Products – Second Review
    k) Tirzepatide (Zepbound) for OSA (Incretin Mimetics for Non-Diabetes Indications) – Second Review
10. Miscellaneous
    a) DUR Digest Vol. 37, No. 2 – Initial Review
11. MedWatch
    FDA adds Boxed Warning about a rare but serious allergic reaction called anaphylaxis with the multiple sclerosis medicine glatiramer acetate (Copaxone, Glatopa)
12. Adjournment

*Individuals attending meetings of the DUR Commission shall have an opportunity to address the Commission. This opportunity will be granted once during the open portion of the meeting. In order to accommodate all interested parties, all speakers are requested to limit their comments to **5 minutes or less**. If you represent a drug manufacturer as an employee, as a contractor, as a member of the manufacturer's Speaker Bureau, or by any other means, we expect you to cover your individual product or entire product line in that five-minute time frame. Speakers who represent multiple manufacturers will share their 5 minutes with the other manufacturer representative(s) whose product they are speaking on. Any individual speaking, presenting, or providing written comment must register and complete a conflict-of-interest disclosure. Registration and completed forms must be provided to DUR staff at least one week prior to the scheduled meeting at pba_iadur@optum.com. Failure to register and submit a complete conflict-of-interest disclosure form by the specified date and time will result in a delay of your comments being considered until the next scheduled meeting. Reference complete public comment policy here.

www.iadur.org

For more information, contact the DUR Project Coordinator, Pamela Smith, R.Ph., at pba_iadur@optum.com or (515) 974-3131.

Next Meeting
August 6, 2025
Meeting Format: TBD